Background Obtaining accurate histopathologic detail for breast lumpectomy specimens is challenging because of sampling and loss of three-dimensional conformational features with conventional processing. The whole-mount (wm) technique is a novel method of serial pathologic sectioning designed to optimize cross-sectional visualization of resected specimens and determination of margin status.
INTRODUCTION
Contemporary breast cancer management commonly involves the surgical resection of breast tumours with curative intent. With the routine use of screening mammography, breast cancers are increasingly identified at an early stage, in which small tumour size permits lumpectomy with preservation of the remaining breast parenchyma [1] [2] [3] . The extent of surgical excision is guided by tumour dimensions as inferred from preoperative imaging. However, beyond the detection of gross disease, microscopic assessment with post-surgical histopathologic processing of the lumpectomy specimen is critical to determining the probability that in situ or invasive disease of clinical significance could remain in the breast.
Pathologists systematically assess the breast lumpectomy at the cut surgical margin for viable tumour cells, known as a positive margin. Awareness of positive margin status, a known predictor of local relapse 4, 5 , allows for accurate counselling of the patient about the potential value of additional surgery for disease clearance and an estimation of the probability of cancer recurrence.
Conventional histopathologic processing of breast specimens has several limitations. Ex vivo specimen handling is limited by the inherent flaccid scaffolding of fatty tissue and the accompanying difficulty in maintaining three-dimensional shape and orientation 6, 7 . Furthermore, lumpectomy specimens are representatively sampled in 10-40 small slides, thereby characterizing only 0.007% -0.02% of the entire volume of resected tissue 8 . Under-sampling of disease can affect the accurate determination of tumour size and the presence and extent of positive margins 9, 10 .
Whole-mount (wm) processing is a pathology technique established to serially section breast lumpectomy specimens in their entirety while preserving threedimensional conformation and orientation and allowing for a more precise assessment of the relative relationship between tumours and margins. Compared with standard processing, the wm method allows for an evaluation of 30 times more tissue 8 . The fresh specimen is suspended in a gel to reduce tissue collapse and distortion, and then serially sectioned into uniform 4-mm slices suitable for processing, staining, and interpretation 8, 11 . The method has been refined and demonstrates preservation of cellular morphology, reduction in specimen shrinkage, compatibility with standard breast cancer immunohistochemistry, and superiority to standard processing with respect to evaluating specimen orientation and volumetric extent of disease [12] [13] [14] [15] . Furthermore, the wm process is the backbone for slide digitization and three-dimensional reconstructive imaging, thus providing unparalleled interpretation of the entire resected specimen.
The adoption of wm processing has several advantages, but also creates several possible downstream issues. The widespread use of wm technique is expected, as greater volumes of tissue are analyzed, to result in more positive margins being reported. The increase in such reports would, in turn, have short-and long-term consequences. More operations for disease clearance will occur and place strain on an already overburdened health care system. However, a short-term rise in operative intervention might ultimately be balanced by improved rates of disease recurrence and survival, although the time to that potential equilibrium is as yet unknown. Furthermore, the relative patient value stemming from more upfront treatment in the form of possible margin re-excision compared with appropriate treatment at the time of recurrence is unknown. Achieving an understanding of those trade-offs is critical.
The goal of the present work was therefore to generate a cost-effectiveness analysis comparing wm serial sectioning of breast lumpectomy specimens with standard pathologic processing over a 10-year horizon.
METHODS

Model Structure
To make the comparison of interest, we constructed a Markov chain cohort simulation model ( Figure 1 ). First, the sensitivity and specificity of positive margin detection were compared for the wm and conventional techniques, and then the consequences of repeated surgery for positive margins was modelled. Sensitivity and specificity values for wm were defined based on a "positive margin" being the presence of tumour cells 0.1 mm or less from the cut edge 16 , with sensitivity analyses (discussed later in this section).
After completion of primary surgical therapy, patients proceed to any one or some combination of adjuvant chemotherapy, trastuzumab therapy, radiation therapy, and endocrine therapy at rates described in the literature. Patients were then placed under surveillance and entered into the Markov model. A Markov model was appropriate for this scenario because it incorporates ongoing risks (for example, cancer recurrence and death) throughout the time horizon and allows for the use of sensitivity analyses to assess variation in key parameters.
The 10-year time horizon for our analysis reflects the median time to local recurrence after breast-conserving surgery in early breast cancer (54 months 5 ) and the fact that endocrine therapy is typically applied over a 5-to 10year period. A cycle length of 1 year was chosen, because 12 months is the common interval for recall clinical examinations and surveillance mammography.
The analysis was conducted using the TreeAge Pro 2014 software application (TreeAge Software, Williamstown, MA, U.S.A.).
Base Case, Markov States, State Transitions, and Probabilities
The base case was a 61-year-old woman undergoing breastconserving surgery for a stage i cancer 17 Table i) . Probabilities were calculated based on reported event rates, using p = 1 -e -rt , where p is the probability for a 1-year period, r is the annual rate of an event, t is time in years, and e is the natural logarithm. Patients in the Death and Best Supportive Care states remained in those states to the end of the time horizon.
To build a robust and clinically appropriate model, these key assumptions were made:
n If patients initially underwent breast-conserving surgery, they underwent mastectomy at the time of recurrence. n Patients in the Metastatic Recurrence or Best Supportive Care states did not undergo surgery, and the former group received chemotherapy. n Only 1 local recurrence was modelled within the time horizon. n Patients with tumours overexpressing her2 (the human epidermal growth factor 2) received trastuzumab alone, because accurate costs for pertuzumab, trastuzumab emtansine, and combination therapy were not yet available in the province of Ontario. n Prophylactic surgery, reconstructive surgery, neoadjuvant therapy, and clinical trials were not included.
Costs
Costs were calculated from the perspective of the Canadian health care system, recognizing that this universal government-funded system pays for hospital-based procedures, in-hospital drugs, and compensation of health care providers. All costs were inflated to 2014 Canadian dollars, adjusted based on the Canadian consumer price index, health care component. Costs are discounted at 3% for future expenditures. The Ontario Schedule of Benefits for Physician Services (2015 version) 27 was used to estimate physician costs associated with pathology and delivery of surgery, chemotherapy, and radiation (Table ii) . Fixed capital costs for equipment purchase, installation, safety assurance, and maintenance contracts were not included, because those costs are borne across all disease sites requiring pathology processing. Costs for processing in both the wm and conventional arms included costs related to materials and quality control procedures, and the hourly rates for pathology assistants and medical laboratory technologists (based on union-controlled 2014 institutional rates). No costs were assigned to fixation and processing times that do not involve human labour. Times (hours) required for wm and conventional processing were derived from institutional estimates by Sunnybrook Health Sciences Centre based on currently accepted protocols 8 and 59 completed wm lumpectomy cases, for which research ethics board approval was obtained.
At the start of each 1-year cycle, the costs of screening mammography are incurred. Once a recurrence or metastatic disease is diagnosed, costs of unilateral ultrasonography, core biopsy, and staging with computed tomography imaging (chest, abdomen, pelvis) and bone scan are included.
Costs for surgery include physician and hospitalrelated costs. The hospital-related costs were obtained from the Ontario Case Costing Initiative, with sensitivity analysis ranges that included costs for potential postoperative infection. A mean estimate was used in the base case, with sensitivity analyses reflecting various surgical procedures (for example, mastectomy with sentinel lymph node biopsy vs. axillary lymph node dissection) and quoted provincial hospital variation. Surgical costs were counted once, within the cycle in which they occurred.
Costs for radiation are based on a 50-Gy regimen in 25 fractions without boost and include costs for physician oversight and radiation therapist time for administration. Chemotherapy costs in the base case are reported as averages for first-, second-, and third-line regimens used in the province of Ontario 29 , and costs for trastuzumab include costs for a loading dose (8 mg/kg) and a maintenance dose (6 mg/kg) every 3 weeks for 1 year for a 70-kg woman. The trastuzumab regimen also includes costs for administration of concurrent paclitaxel and for cardiac monitoring 26 . Endocrine therapy costs are weighted based on the relative proportions of patients in the Ontario Drug Benefit program (patients > 65 years of age) undergoing treatment with either tamoxifen or an aromatase inhibitor. The latter is costed using letrozole for a 5-to 10-year period 30 .
Outcomes
Outcomes are represented as quality-adjusted life years (qalys), incorporating utilities for 4 unique states: well with no recurrence, metastatic disease on chemotherapy, local recurrence, and best supportive care (Table i) 25, 26, 32 . Utilities reflect known adjustments for a given state of health and were multiplied by the length of time in each state. Those values were subsequently totalled to create the final number of qalys 33 . Cost effectiveness is quantified by the incremental cost-effectiveness ratio (icer)-that is, the incremental cost per additional qaly gained or lost.
Sensitivity Analyses
Our model contains two major sources of uncertainty: uncertainty in the input clinical parameters, and uncertainty in the model calculations. Sensitivity analyses addressed both of those issues. One-way and multiway deterministic sensitivity analyses were completed to address uncertainty in input clinical parameters over the ranges shown in Tables i and ii, as derived from the literature and institutional experience with pathology techniques. To address model uncertainty, stochastic probability-based sensitivity analyses and Monte Carlo simulation with 10,000 trials were performed to generate sampling distributions associated with the calculation of costs and outcomes. Distributions for each strategy were combined to form net monetary benefit distributions over a range of willingness-to-pay (wtp) thresholds. Net monetary benefit [calculated as (effectiveness × wtp) -cost], which is less statistically unstable when small changes in effectiveness are observed and distributions are nonparametric, was used to facilitate the transparent comparison of interventions 34 . Net monetary benefit distributions generated from simulation analyses were then plotted in a cost-effectiveness acceptability curve to graphically represent the probability of each strategy being cost-effective at each wtp threshold between $0 and $100,000 35, 36 .
RESULTS
The average per-case cost of wm processing for breast lumpectomy specimens is greater than that for conventional processing ($19,988 vs. $18,427), and wm processing incurs 19% more operations after initial treatment (including a possible margin re-excision or mastectomy) is complete. However, over a 10-year time horizon, wm processing generates 0.03 more qalys. The resulting icer indicates that each additional qaly resulting from the use of wm processing costs the health care system $45,414 (Table iii) . At the completion of 10 cycles, 85.6% of patients were alive with no recurrence, 4.3% had metastatic disease, and 3.7% had died.
Deterministic one-way sensitivity analyses demonstrated the robustness of the model and its preferred treatment strategies for all tested values and showed the most sensitivity to changes in the positive margin prevalence. As indicated in Figure 2 , a lower prevalence of positive margins increases the icer to a tested maximum of $100,607 at a prevalence of 10.3%.
Probabilistic sensitivity analyses using Monte Carlo simulation generated a cost-effectiveness acceptability curve in which wm is the preferred strategy at a wtp threshold exceeding $45,414 (Figure 3 ).
DISCUSSION
The present cost-effectiveness analysis, which followed patients for a 10-year period, generated average per-case costs that were higher for patients whose lumpectomies were processed initially with the wm technique (compared with conventional techniques). A modest 0.03 increase in qalys in the wm group arose from the significantly higher sensitivity of the wm technique to detect positive margins and a consequent downstream reduction in local and systemic recurrences. However, given that recurrence rates with conventional processing of breast lumpectomies are already low at baseline, any incremental difference generated solely from the wm technique ultimately result in small changes in overall life-years and in qalys.
But changes in clinical cost-effectiveness are accompanied by the associated benefits of adopting the wm technique, including a comprehensive three-dimensional assessment of the lumpectomy specimen and the more accurate correlation of tumours to their respective margins. Obtaining those details is truly novel, because conventional processing can miss or misrepresent those relationships because of extensive tissue processing and sampling. Accurate margin assessment could help to guide more informed use of adjuvant therapies such as chemotherapy and radiation. Additive to the present cost-effectiveness study is an anticipated improvement in time efficiency experienced by breast pathologists; that effect will be reported separately in work forthcoming from our research team.
When interpreting the present analysis, it is important to reflect on the definition of a "positive margin," because that definition has been extensively debated. The literature is replete with several reported definitions of positivity after lumpectomy, with thresholds ranging anywhere from 1 cm to no-tumour-on-ink. In a recent comprehensive metaanalysis and multi-organizational consensus statement 5, 37 , experts stated that the critical threshold for declaring margin positivity is no-tumour-on-ink, because achieving wider margins did not, in the modern era, reliably lead to better clinical outcomes. Given that statement, fewer reoperations for positive margins-based on margin width alone-are anticipated to take place in future, although the precise clinical consequences of widespread change in practice remain to be seen. The quoted sensitivity and specificity ranges for wm processing in the present analysis reflect a threshold of 0.1 mm as a practical implementation of no-tumour-on-ink. However, to ensure model robustness, tested sensitivity ranges for the prevalence of positive margins reflect variations in clinical interpretation. The challenge of interpreting the present cost-effectiveness analysis comes in contextualizing the icer within the landscape of the cost that hospital administrators and health policy advisors are willing to pay for interventions for the care of breast cancer patients. In essence, an icer of $45,414 indirectly represents an investment in secondary prevention, whereby the attempt to identify positive margins as accurately as possible averts a subsequent breast cancer recurrence. Studies in breast cancer care demonstrate that patients with metastatic breast cancer are willing to spend between US$1,458 and US$3,894 annually to avoid the adverse effects of chemotherapy-based cancer treatments 38 . Current wtp estimates for prevention programs in breast cancer range from US$9,860 per lifeyear saved for chemoprevention in high-risk patients, to US$21,577 per life-year saved for mammography every 2 years for women 40-49 years of age, to US$137,922 per lifeyear saved for chemoprevention for all breast patients 39 . The icer of $45,414 in the present study therefore does not seem inconsistent with the costs for other strategies considered for harm reduction in breast cancer.
Evidence also indicates that cost-effectiveness thresholds for the adoption of health care interventions might differ based on the payment structure of the relevant health care system. In the United Kingdom, £20,000-£30,000 per qaly has been accepted as the threshold to adopt new health care technology, with the U.S. threshold being US$50,000-US$100,000 40 . However, those thresholds are not based on scientific evidence, have not adapted to inflation over time, and have been criticized for being too low 41, 42 . Furthermore, in prevention studies, wtp estimates have been found to decline approximately 1.5% per year of latency (time from risk exposure to onset of cancer) 43 .
In Canada, Laupacis et al. 44 described a schema whereby an icer of less than CA$20,000 per qaly (equivalent to CA$29,857 in 2014 Canadian dollars) constituted strong evidence for adoption and appropriate utilization of an intervention, and thresholds of CA$20,000-CA$100,000 and more than CA$100,000 ($148,287 in 2014 Canadian dollars) constituted moderate and weak evidence respectively. In a recent international appraisal to assess the value of an additional qaly in Japan, Korea, Taiwan, the United States, the United Kingdom, and Australia, wtp thresholds were found to vary widely, being £23,000 per qaly in the United Kingdom and US$62,000 in the United States 40 . Interestingly, a relationship was detected between wtp threshold and the proportion of private expenditure on health, whereby populations with a higher proportion of market-driven investment in health care were willing to pay more per qaly for a new intervention 40 , even after adjustment for variations in intrinsic national wealth. Clearly, determinations of estimated wtp are context-specific and require consideration of the burden of disease, the scope of the population affected, and the fluidity of the budget. Estimates below $100,000 appear to be reasonable for consideration, but each decision requires thoughtful deliberation by all parties involved.
Our cost-effectiveness analysis has limitations. The sensitivity and specificity values for the wm process were based on data from a single institution and are difficult to report with certainty, because wm is assumed to be the most accurate-the "gold standard." However, sensitivity analyses using variations in those values within clinically plausible ranges showed that the overall results of the model were robust.
CONCLUSIONS
Adoption of routine wm processing for breast lumpectomy specimens from patients with early breast cancer requires an investment of $45,414 for each additional qaly gained. In addition, implementation of the method could require capital investment for equipment (for example, a slicing machine for large slides) and training of pathology assistants and medical laboratory technologists. Those expenditures are significant. Given the fixed or shrinking health care budgets in the current economic climate, such an investment will require disinvestment in another theoretically less efficacious intervention. To mitigate largescale swings in cost, gradual adoption of the wm method might be envisioned, or implementation of a hybrid model of handling in which patients at higher perceived risk for close or positive margins (for example, multifocal disease, large areas of mammographic calcifications, known ductal carcinoma in situ) might best be treated with wm, because they are most at risk for under-identification of positive margins and consequently might benefit most from the "prevention" aspect of this novel technique.
